Safe Space Technology™

TORONTO, ON / ACCESSWIRE / November 18, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) ("Kontrol" or "Company") is pleased to provide an update on its BioCloud technology development.

"Our team continues to execute on the vision to create and bring to market a safe space technology," says Paul Ghezzi, CEO of Kontrol.

Distribution Agreements

The Company intends to sell BioCloud directly to various potential customers. At the same time the Company is pursuing both exclusive and non-exclusive distribution channels for BioCloud sales. Kontrol is pleased to announce it has entered into two non-exclusive BioCloud distribution agreements. The distribution agreements cover Ontario and Saskatchewan.

The Company has also entered into discussions with various parties for potential industry exclusive distribution agreements which would require minimum unit quantity orders.

New Website

Kontrol has launched a new website for BioCloud. For more information please visit www.kontrolbiocloud.com.

Name Change

Kontrol Energy Corp. is in the process of changing its name to Kontrol Technologies Inc. The name change is anticipated to take place by the end of December 2020.

Cash on Hand

As of November 17, 2020, the Company has $3.8 Million of cash on hand.

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE:KNR)(OTCQB: KNRLF)(FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada's fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean's.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.

For further information, contact:

Paul Ghezzi, Chief Executive Officer
paul@kontrolenergy.com or admin@kontrolenergy.com
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company's product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol's lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

ReleaseID: 617251

The Voluntary Escrow serves further validates investors belief and support of Havn Life's business plan and future growth strategy

VANCOUVER, BC / ACCESSWIRE / November 18, 2020 / Havn Life Sciences Inc. (CNSX:HAVN) (FRA:5NP) (the "Company" or "Havn Life"), is pleased to announce that certain shareholders have entered into voluntary escrow agreements with the Company pursuant to which an aggregate 6,300,000 common shares will be subject to a contractual resale restriction until March 8, 2021 (the "Escrowed Shares"). The Escrowed Shares were originally subject to a four-month statutory hold period which will expire on January 8, 2021.

"Havn Life has always appreciated the support of its staff, management and shareholders. This voluntary escrow only confirms our major shareholders confidence and commitment to what we are building. I would like to personally thank our shareholders for sharing our belief in our vision and our Company's future upside." commented Tim Moore, CEO of the Company. "The team is continuing to diligently work towards reaching our goals and milestones over the coming 12 months.

On Behalf of The Board of Directors

Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Contact:

Investor Relations: ir@havnlife.com 604 687 7130
Media: brittany@exvera.com 778 238 6096

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

SOURCE: Havn Life Sciences Inc. 

ReleaseID: 617253

LOS ANGELES, CA / ACCESSWIRE / November 18, 2020 / This is why I set a standard that I deserve more in life so I took that plunge into building my side hustle empire to create a profound future for myself.

Born and raised in a small rural town in Thomasville, Alabama, I was blessed to have loving parents who instilled a strong work ethic in their baby girl. My parents worked hard to provide me opportunities and a future that included a good school, a college degree and a high-paying job with benefits. In short, my parents wanted nothing less for me than the classic American dream. Isn't this how society views success today?

Good Education + Hard Work + High-Paying Corporate Job = Fulfillment & Joy

Unfortunately, nobody tells you that the American dream was never designed to make you wealthy or fulfilled. They certainly didn't teach you this in school. Twenty years into my so-called "American Dream" I found myself in Orlando, Florida as a leader in a major distribution company where my role wasn't just to sale & market products. My #1 responsibility was to create bright young leaders among the organization. I was to provide an atmosphere of open communication, encouragement & servant leadership…all the qualities I inherited over my corporate journey. However, there was still something missing in my life. I was blissfully dissatisfied. And literally, a Godsend appeared and connected me with a group of DIGITAL ENTREPRENEURS who were inspiring lives across the world to obtain a better quality of life – personally & financially. As I learned from these aspiring young leaders I totally caught myself being tugged into a new-found path. A pathway to time & financial freedom that would allow me to live a life created & designed by ME with no limitations. As I took the plunge into creating my side hustle empire, I studied investing and how money truly works and later understood that hard work (my job) will never get me to my dreams & goals if I continue working for someone else. This is true for you as well if you have big dreams & goals, or simply want freedom. So what if I could continue my leadership journey in corporate all while following my true passion: helping other people build and scale their own brands and businesses to find financial freedom?

Maybe that outline is a bit too complicated and dramatic for you, but if you are anything like me, you deserve more out of your life too. Never in a million years did I think a little girl from Thomasville would be part of a DIGITAL GLOBAL business impacting lives across the world. In a society where we've had our privileges & rights taken from us I've been called to a higher power to help people gain the confidence and personally develop, all while creating time & financial freedom. You see…if you're successful, people will step on you! If you're not successful, people will step on you! If you struggle with self-confidence they'll step on you! So it's up to you to build that mindset, that skillset, the determination, the gut to step up & invest in yourself. You see, it's not about the personal success I crave, it's about sharing my world-class mentorship program & inspiring people to action. To become a better version of themselves. We are in the information era, it's about personal success, becoming bigger than your problems and becoming the best version of you!

With my mentorship program from the 20+ years in corporate training from sales, to marketing, to leading a sales team, I have not only found a passion that gives me purpose and drive in my own life, but I have had countless opportunities to guide others in their own career awakening. I've seen my team and colleagues embrace new healthy ideas, new financial situations, new attitudes, all as a result of a positive mindset mixed with the proper information and tools. My philosophy also means that what you put in, you get back. We attract what and who we are. My goal is to encourage and mentor those in my world to embrace the growth while accepting the struggle in order to create a great life. Maybe you're a dreamer & doer. If so, maybe you've been looking for someone that finally has the results unlike these online guru's making empty promises.

As the days turn into weeks, and weeks turn into months and years, you can begin to look back on your life and wonder like I did after 20 + years of giving my life to corporate: Is this all there is to my life? Folks, I'm here to tell you, multiple streams of income are no longer a luxury, it's a necessity! Now is the time to step up & take massive action in your life because you deserve it!

If you aspire to create a better life for yourself and learn more on how to get started chasing your passion and escaping the 8-5, contact me today! I'd love to chat and see if you're a good fit.

Or if you feel we might have something in common work wise, I'm always open to be a source of strength, information and encouragement to those who seek it.

Blessings,

Mandy Smith

joinmmat.com/mandy
IG: www.instagram.com/manlynsmith

Media Details

Website URL: http://www.ascendagency.net/
Company Name: Ascend Agency
Email address: Contact@AscendAgency.net
Country: USA

SOURCE: Ascend Agency

ReleaseID: 617295

Veteran Pharmaceutical Industry Executives Will Advise Portfolio Companies and Investment Team

TORONTO, ON / ACCESSWIRE / November 18, 2020 / Lumira Ventures, a leading North American healthcare venture capital firm, today announced the appointment of Theodore Witek, Jr., DrPH, MBA and Daniel Billen, PhD to the role of Special Advisor, and Sena Biswas, PhD, MBA as Venture Partner.

"We are excited to welcome Ted, Daniel and Sena to the Lumira Ventures team," commented Peter van der Velden, Managing General Partner of Lumira Ventures. "With over 100 years of combined experience in the pharmaceutical and biotechnology industries, they will bring invaluable strategic and operational input to our portfolio companies and assist our investment team in the identification, evaluation and building of new companies developing transformative biomedical innovations."

Dr. Witek has over three decades of clinical development and executive leadership experience. After joining Boehringer Ingelheim in 1992, as leader of the Respiratory and Immunology clinical research groups he led the global clinical development and launch of several respiratory products, most notably Spiriva®, and eventually served as President and CEO of Boehringer Ingelheim's Canadian and Portuguese operations. He served on the Board of Directors of Canada's Research-Based Pharmaceutical Companies (Rx&D) and was the Chair of the Health Technology Assessment Committee. He also served over ten years on the Drug/Device Discovery and Development Committee of the American Thoracic Society, serving as Chairman from 2010 to 2012. Dr. Witek was appointed to the Ontario Health Innovation Council and is currently Adjunct Professor and Senior Fellow at the Institute of Health Policy Management & Evaluation at University of Toronto. He holds a Doctor of Public Health degree from Columbia University, a Master of Public Health from Yale University, and a Master of Business Administration from Henley Management College.

Dr. Billen brings over 40 years of experience in the commercialization of pharmaceutical and biotechnology products in North America and Europe. He started with Janssen in their Belgian headquarters in cardiovascular global marketing, later becoming head of marketing and sales for Janssen's newly formed affiliate in Canada where he launched multiple products into the Canadian market. Dr. Billen joined Amgen in 1991 to lead its Canadian operations as the company's first General Manager. He later moved to Amgen's headquarters in California where he led the U.S. commercial operations business unit and later the combined nephrology and inflammation business unit as Vice President and General Manager. He later served as Amgen's Vice President of Global Commercial Initiatives with a focus on the evolving U.S. payer landscape. Since April 2019, Dr. Billen has been a director of Lumira portfolio company Aurinia Pharmaceuticals (Nasdaq: AUPH). Dr. Billen received his PhD in chemistry from the University of Louvain in Belgium.

Dr. Biswas has over three decades of experience as a biotechnology CEO, researcher, business development executive and venture capital investor. He has recently served as interim CEO at Mimetogen Pharmaceuticals and at Lumira portfolio companies KalGene Pharmaceuticals and OsteoQC. For over thirteen years he was a Managing Director at VIMAC Ventures, an early-stage life sciences venture capital firm in Boston. He was the first employee and President of Merrimack Pharmaceuticals which subsequently grew to a peak market capitalization of over $1.5 billion and successfully launched a cancer drug. Earlier in his career, Dr. Biswas was Director of Business Development at Rhone-Poulenc Rorer executing over 100 licensing and M&A transactions; Principal at TL Ventures, a $1.4 billion venture capital firm where he invested in the Series A rounds of Esperion, Adolor, ViroPharma, all of which became NASDAQ listed companies; and member of the Healthcare Investment Banking team at Bear, Stearns & Co. He holds a BA in Biology from Brandeis University, a PhD in Molecular and Cellular Biology from the University of Pennsylvania, an MBA from the Wharton School, and completed a postdoctoral fellowship in molecular immunology at Harvard Medical School.

About Lumira Ventures
Since our founding in 2007, Lumira Ventures has a built a track record as a leading North American healthcare venture capital firm, investing in innovative companies in the biotechnology, medical device, digital health and consumer health sectors. Our goal is to partner with entrepreneurs in Canada and the U.S. to build companies from the seed through growth stages whose products deliver transformative improvements in the lives of patients worldwide. Our companies have brought dozens of biomedical innovations to the market impacting the lives of over 1 billion patients and generating over $70 billion of cumulative revenue. Lumira Ventures has offices in Toronto, Montréal, Vancouver and Boston. For more information, please visit www.lumiraventures.com.

Contact Information
Peter van der Velden
Managing General Partner
plv@lumira.vc

SOURCE: Lumira Ventures

ReleaseID: 617220

VANCOUVER, BC / ACCESSWIRE / November 18, 2020 / Tracker Ventures Corp. ("Tracker" or the "Company") (CSE:TKR) (OTC:TLOOF) (FWB:B2I) today announced that its to-be-subsidiary Contakt LLC ("Contakt World"), a technology company modernizing the contact tracing process, will present at the Diamond Equity Research Emerging Growth Invitational investor conference taking place virtually December 1, 2020.

Justin Beck, CEO of Contakt World, is scheduled to host a virtual presentation to investors, followed by a guided question and answer session as follows:

Diamond Equity Research Emerging Growth Invitational

Date: December 1, 2020
Time: 4:20 p.m. Eastern time
Webcast: https://us02web.zoom.us/webinar/register/WN_MbKy3IugRIeqVyWdbDlYTg

A live audio webcast and archive of the conference presentation will be available using the webcast link above. For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative.

Contakt World – Tracker Transaction

Tracker and Contakt World are parties to a definitive share exchange agreement pursuant to which Tracker will indirectly acquire (the "Acquisition") a 100% interest in Contakt World. For further information respecting the Acquisition, please refer to the Company's news release dated October 30, 2020. Trading of Tracker's shares on the Canadian Securities Exchange (the "CSE") has been halted in connection with the announcement of the Acquisition and is not expected to resume until the CSE has approved a Form 2A Listing Statement for the resulting issuer from the Acquisition. There can be no assurance that the Acquisition will be completed on the terms proposed in the share exchange agreement or at all.

About Contakt World

Contakt World is a data technology company innovating the contact tracing process, with the goal of becoming the most trustworthy, accessible and scalable contact tracing and health surveillance system globally. Contakt World combines aggressive research and development, next-gen data integrations and strategic health partnerships to empower and build mutual trust within communities, all contributing towards health equity and the reduction of healthcare disparities for users around the world. For more information, please visit the Company's website at www.contakt.world.

About Tracker Ventures Corp.

Tracker Ventures (CSE:TKR; OTC:TLOOF; FWB: B2I) is an analytics software company that leverages blockchain and digital asset technology to transform and modernize multiple industries. Tracker is taking a diversified approach to the analytics and technology space, delivering practical solutions in the health, finance, logistics and pharmaceutical industries. The Company's turnkey real-time tracking solutions offer the very latest in IoT and AI, providing valuable data and business intelligence to some of the world's leading brands. For more information, please visit www.tkrventures.com.

Tracker Ventures Contact

Geoff Balderson
CEO and Director
Direct: 604-602-0001

Contakt Investor Contact

Lucas A. Zimmerman
Senior Vice President – MZ North America
Direct: 949-259-4987
contakt@mzgroup.us
www.mzgroup.us

Contakt Media Contact

Kevin Harrington
Account Director – 5WPR
contaktPR@5wpr.com

The CSE has not reviewed, approved or disapproved the content of this news release.

SOURCE: CONTAKT LLC

ReleaseID: 617131

EL CAJON, CA / ACCESSWIRE / November 18, 2020 / Solar Integrated Roofing Corp. (OTC PINK:SIRC), an integrated, single-source solar power and roofing systems installation company, announced today that it has realized record revenue quarter-to-date, seeing revenues of greater than $3.3 million for the months of September and October 2020.

"The third quarter of 2020 has been highlighted by continued growth of our highly complementary solar and roofing businesses," said David Massey, Chief Executive Officer of Solar Integrated Roofing Corporation. "With supportive industry trends driving increased solar adoption and our significant cross selling opportunities across solar, battery backup installation, roofing and related HVAC/electrical contracting work, we have driven what I expect to be a record third quarter, with year-over-year revenue growth in excess of 50% to $3.3 million at an expected 40% gross margin for the months of September and October 2020.

"As we continue to achieve scale through acquisition, such as our recently announced HVAC acquisition or potential future Enerev acquisition after the completion of our 30-day joint venture, I would expect continued record-breaking results for us as we fully realize the immense cross-selling benefits that face us today," concluded Massey.

About Solar Integrated Roofing Corp.
Solar Integrated Roofing Corporation (OTC PINK:SIRC), is an integrated, single-source solar power and roofing systems installation company specializing in commercial and residential properties in the Southern California market. For more information, please visit the Company's website at www.solarintegratedroofingcorp.com.

Forward-Looking Statements
Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update the information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Investor Relations Contact:
Lucas A. Zimmerman
Senior Vice President
MZ North America
Main: 949-259-4987
SIRC@mzgroup.us
www.mzgroup.us

SOURCE: Solar Integrated Roof Corp.

ReleaseID: 617230

Market players are focusing on extending market penetration through mergers and collaborations and product launches to gain a competitive advantage.

DUBAI, UAE / ACCESSWIRE / November 18, 2020 / The bamboo products market will expand at a CAGR of 6% over the forecast period, 2020-2030. The market is primarily driven by surging focus on availability and sustainability of affordable bamboo products.

"Prominent bamboo manufacturers are supporting potential importers in consolidating and developing bamboo farms under stimulated settings." concludes the FMI analyst.

Request a report sample to gain comprehensive market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-12758

Key Highlights

East Asia to lead among other regions, relying majorly on China, the global bamboo capital.
Commercial end-users is expected to account for around 40% of revenue share across the forecast period
Online sales of bamboo product will exceed US$ 10 Bn towards 2021 end, due to high dependence on e-commerce platforms amid the COVID-19 crisis.
Lifestyle products to witness high demand due to increased purchases of home décor products & furnitures.

Drivers

Surge in timber prices has encourage market for bamboo products particularly as construction materials.
Growing use of sustainable construction/building resources, and growing consumer awareness in relation to the benefits and uses of bamboos will fuel the market growth.
Introduction of eco-friendly products such as bamboo toothbrushes and disposables are creating credible growth prospects.

Restraints

East Asia has been a sole contributor of bamboo products across the globe, this has limited the presence of manufacturers in the global market.
Lack of awareness as regards market prospects is impacting market expansion.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-12758

COVID-19 Impact on the Market

The onset of the COVID-19 pandemic has decelerated the yearly growth in 2020 to 3.3% in contrast to 2019 on account of government imposed lockdowns. However, the sluggishness is estimated to drop by 2021 as governments are safeguarding bamboo cultivators from the pandemic's recessionary shocks.

Competitive Landscape

Key market players operating in the bamboo products market are Bamboo Village Company, Moso International BV, Kerala State Bamboo Corporation, Smith & Fong Company, Shanghai Tenbro Bamboo Textile Company, Huayu Group, Xiamen HBD Industries and Trade Company, Pappco Greenware, Bamboo Master, Jiangxi Bamboo Technology Development Company Ltd. and Meysher Industrial Group. Manufacturers are engaged in product launches to gain a competitive advantage over others. For instance

Moso International BV took over Bambeau Becker and Groβgarten GmbH located in Frechen, Germany. The acquirement is likely to assist Moso to improve its presence in the international market.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-12758

About the Study

The study offers readers a comprehensive assessment of the bamboo products market. Global, regional and national-level analysis of the latest trends influencing the market is covered in this FMI report. The study provides insights according to product type (lifestyle products, building and construction products, packaging and storage products, educational and recreational products), sales channel (online and offline), end-user (personal and residential, commercial, industrial and infrastructure) across key regions (North America, Latin America, Europe, China, Asia Pacific, Middle East & Africa).

Explore FMI's Coverage of the Consumer Product Industry

Vegan Footwear Market: Get insights on the vegan footwear market through FMI's report covering detailed quantitative and qualitative analysis for projection period 2020 – 2030.

Anti-pollution Ingredients Market: FMI's exhaustive study on the global anti-pollution Ingredients market covers the latest trends, innovations, key players, and popular strategies for the period 2019 – 2029.

Compostable Toothbrush Market: Obtain detailed analysis on the compostable toothbrush market through FMI's report covering competitive analysis, key regions, and segmental analysis for 2019 – 2029.

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/bamboo-products-market
Press Release Source: https://www.futuremarketinsights.com/press-release/bamboo-products-market

SOURCE: Future Market Insights

ReleaseID: 617281

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK / ACCESSWIRE / November 18, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, today announces that it has entered into a convertible loan note financing facility (the "Facility") with Mint Capital Limited ("Mint Capital") pursuant to which it has conditionally agreed to issue up to £60 million in aggregate principal amount of convertible unsecured loan notes (the "Convertible Loan Notes") to Mint Capital.

Mint Capital is a Bahamas-based investment management company which specialises in providing growth capital to companies around the world.

The Facility will be made available to the Company subject to certain conditions being met. After the issue of the first tranche of £12 million in principal amount of Convertible Loan Notes, use of the Facility will be solely at the discretion of the Company. Further details about the terms and conditions of the Convertible Loan Notes are set out below under "Further details of the Convertible Loan Notes".

The Facility will allow Hemogenyx Pharmaceuticals to accelerate and broaden its development pipeline of novel therapies and treatments for blood cancers and viral diseases. It will also strengthen the Company's negotiating position with both existing and future partners. Further details of the intended use of proceeds are set out below under "Use of proceeds".

The issue of the Convertible Loan Notes is subject to, amongst other things, the Company obtaining shareholder approval to grant the Company's directors (the "Directors") the necessary authorities to issue the Convertible Loan Notes and the Company having published a prospectus approved by the U.K. Financial Conduct Authority (the "FCA").

The Company's CEO, Dr Vladislav Sandler, commented, "Our various product candidates have shown great results in our laboratory research and testing, and the Company is poised to move our product candidates into proof of concept and clinical studies. This significant facility will enable Hemogenyx Pharmaceuticals to move our life-saving technologies forward rapidly, placing the Company in a highly competitive position in the treatment of cancer and viral diseases."

Use of proceeds

The Facility will allow the Company to bring even greater focus to bear on scientific and commercial advances. The funds will enhance Hemogenyx Pharmaceuticals' control over its intellectual property assets under development and give it greater choice in determining what strategic partnerships to pursue and on what terms, enabling it to achieve maximum shareholder value.

Hemogenyx Pharmaceuticals has been successfully progressing in its development of its CDX antibody candidate ("CDX") and its HEMO-CAR-T product candidate. In addition, the Company has carried out considerable preliminary work on the development of its cell therapy platform as a novel means to allow the programming of immune cells to target both viral infections, including COVID-19, and certain types of cancer.

The Company intends to use the net proceeds of the issue of the Convertible Loan Notes to accelerate the development and marketability of its product candidates as follows:

Achieve clinical proof of concept for the Company's CDX bi-specific antibody product candidate if and when needed, including:
completing Investigative New Drug ("IND")-enabling pre-clinical studies that are needed in order to file an IND application requesting authorisation from the Food and Drug Administration ("FDA") or other applicable regulatory body to initiate clinical trials and administer the Company's CDX bi-specific antibody to humans;
filing an IND; and
completing Phase I/IIa clinical studies aimed at achieving clinical proof of concept and advancing the CDX bi-specific antibody toward later stages of clinical trials including Phase II and Phase III.
Achieve clinical proof of concept for the HEMO-CAR-T, including:
completing IND-enabling pre-clinical studies in collaboration with the University of Pennsylvania ("Penn");
filing an IND; and
completing Phase I/IIa clinical studies aimed at achieving clinical proof of concept and advancing HEMO-CAR-T towards later stages of clinical trials including Phase II and Phase III.
Achieve pre-clinical and clinical proof of concept for the Company's cell therapy platform (referred to by the Company as "CBR"), including:
completing the development and validation of CBR as a novel platform that allows the programming of immune cells to target either viral infections or certain types of cancer;
completing IND-enabling pre-clinical studies of an undisclosed CBR-based product candidate;
filing an IND; and
completing Phase I/IIa clinical studies aimed at achieving clinical proof of concept and advancing the undisclosed CBR-based product candidate toward later stages of clinical trials including Phase II and Phase III.
General working capital purposes

Current trading update

CDX Antibodies

Work with a global international pharmaceutical company ("GlobalCo") on the Company's CDX antibody ("CDX") as a clinical candidate, first announced on 14 May 2018, has entered its final phase. The term of the collaboration has been extended twice. The second extension announced on October 27, 2020 runs through the end of 2020. Both extensions were necessary to compensate for the slow down caused by the COVID-19 pandemic. The Company and GlobalCo continue to develop CDX toward clinical readiness and have nearly completed the manufacturability assessment and follow-up tests on the antibody.

Hemogenyx Pharmaceuticals and GlobalCo remain optimistic as to the outcome of these tests based on results to date and look forward to the completion of the scientific development work portion of the collaboration.

CAR-T Agreement with University of Pennsylvania

Hemogenyx Pharmaceuticals entered into a Sponsored Research Agreement ("Research Agreement") with the University of Pennsylvania, as announced on August 11, 2020. The goal of the Research Agreement is to advance the Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") developed by the Company toward clinical trials. The Research Agreement is envisaged as the first step of a larger program that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukaemia ("AML").

The Company is pleased with the progress made to date under the terms of the Research Agreement.

CBR platform

As announced on April 22, 2020, the Company commenced development of a novel treatment for patients suffering from COVID-19. Recognising that the field was saturated with companies competing to develop clinical grade neutralising antibodies to treat COVID-19, the Company demonstrated its expertise and nimbleness, deploying its ingenuity and existing technologies, including its Advanced peripheral blood Hematopoietic Chimera ("ApbHC") (humanised mice), as well as its experience in programming immune cells, to develop a unique approach to combating viral infectious diseases more generally. As a result, the Company has developed a cell therapy platform, which it is calling CBR. The essence of CBR is the programming of immune cells using a novel type of modifiable synthetic receptor to destroy viral pathogens including SARS-CoV-2 which causes COVID-19. Not only can this type of synthetic receptor potentially combat viral pathogens, it can also potentially be modified to program immune cells to destroy malignant cells causing cancer. The novel synthetic receptor has no connection to, and does not resemble, any known or widely used Chimeric Antigen Receptors (CARs, e.g., HEMO-CAR-T), and the Directors are not aware of any direct competitor for this product candidate at this time. Hemogenyx Pharmaceuticals is engaged in pre-clinical validation of two CBR-based potential product candidates: one for the treatment of COVID-19, and the other for the treatment of an undisclosed type of cancer.

Further details of the Convertible Loan Notes

Mint Capital has conditionally agreed to subscribe for up to £60 million in aggregate principal amount of the Convertible Loan Notes pursuant to an agreement entered into today with the Company (the "Subscription Agreement"). The key terms of the Convertible Loan Notes include:

A principal amount of up to £60,000,000, split into denominations of £50,000 per Convertible Loan Note. The Convertible Loan Notes will be subscribed for at par.
The Convertible Loan Notes are to be issued in up to nine tranches. The first tranche of £12,000,000 in principal amount is expected to be issued immediately following satisfaction of the conditions in the Subscription Agreement (the "Initial Issue Date"). The subsequent eight tranches are issuable at the sole discretion of, and in the amounts determined by, the Company at respective intervals of 90 days after the Initial Issue Date. The aggregate maximum principal amount of the Convertible Loan Notes is limited to £60,000,000.
No interest is payable on the Convertible Loan Notes.
The Convertible Loan Notes are unsecured.
Each tranche of Convertible Loan Notes issued is redeemable at par on the date falling 36 months after the relevant Issue Date (the "Maturity Date").
Each of the Convertible Loan Notes is convertible into ordinary shares of £0.01 (1 pence) each in the capital of the Company ("Ordinary Shares") at any time during the period commencing on the fifth business day following the relevant Issue Date and ending at 5.00 p.m. London time on the business day immediately prior to the relevant Maturity Date (the "Conversion Period").
The price used for the conversion (the "Conversion Price") will be equal to a 10 per cent. discount to the lesser of (i) 125 per cent. of the closing-bid price as reported by Bloomberg for one Ordinary Share one trading day before the relevant Issue Date (subject to adjustment to reflect any sub-division or consolidation of the Ordinary Shares) and (ii) the lowest closing bid-price as reported by Bloomberg for an Ordinary Share from the three consecutive trading days ending on the day prior to the date of service of the relevant conversion notice (or if such conversion notice is served after 4.35pm on any such date, then the three consecutive trading days ending on the day such conversion notice is served. In no event shall the Conversion Price be less than the nominal value of an Ordinary Share.
A holder will not be permitted to submit a conversion notice in respect of the Convertible Loan Notes if the total Ordinary Shares held by the holder following the execution of such conversion notice would exceed 29.9 per cent. of the Company's total Ordinary Shares.
Subject to limited exceptions, the Convertible Loan Notes will not be transferable.
Prior to conversion, the Convertible Loan Notes do not entitle the holder to any voting rights in the Company.

Arrangement fee

The Company has agreed to pay a fee of five per cent. of the aggregate principal value of the Convertible Loan Notes issued to the arranger for the Facility (the "Arranger"). Such fee shall be payable by the allotment and issue of new Ordinary Shares, subject to the Directors having the necessary shareholder authorities in place to issue such new Ordinary Shares and the issue of new Ordinary Shares not requiring the publication of a prospectus by the Company. If such fee cannot be satisfied by the allotment and issue of new Ordinary Shares, it shall be paid in cash.

Circular and notice of General Meeting

The issue of the Convertible Loan Notes is subject to, amongst other things, the Company obtaining shareholder approval to grant the Directors the necessary authorities to issue the Convertible Loan Notes. A circular will be sent to the Company's shareholders in due course containing details of the Convertible Loan Notes and to convene a general meeting at which these approvals will be sought.

Other conditions to issue of the Convertible Loan Notes

The issue of Convertible Loan Notes on the Initial Issue Date is conditional on publication by the Company of a prospectus that has been approved by the FCA in respect of the admission of the Ordinary Shares to be issued on conversion of the Convertible Loan Notes to the standard segment of the Official List and to trading on the London Stock Exchange's main market for listed securities. The issue of Convertible Loan Notes on any issue date after the Initial Issue Date is conditional on that prospectus remaining valid or a further prospectus having been published by the Company.

The issue of the Convertible Loan Notes is also conditional upon the Subscription Agreement having become unconditional in all respects in respect of that relevant tranche of Convertible Loan Notes.

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, the person responsible for arranging for the release of this Announcement on behalf of the Company is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukaemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anaemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

Important Notice

This Announcement and the information contained in it is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or from any jurisdiction in which the same would constitute a violation of the relevant laws or regulations of that jurisdiction. No public offering of Convertible Loan Notes is being made in any jurisdiction. The distribution of this Announcement and the offering of the Convertible Loan Notes in certain jurisdictions may be restricted by law. No action has been taken by the Company that would permit an offering of the Convertible Loan Notes or possession or distribution of this Announcement or any other offering or publicity material relating to such Convertible Loan Notes in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company to inform themselves about, and to observe, such restrictions.

There are matters set out within this Announcement that are forward-looking statements. Such statements are only predictions, and actual events or results may differ materially. For a discussion of important factors which could cause actual results to differ from forward-looking statements, refer to the Company's Annual Report and Accounts for the period ended 31 December 2019. The Company does not undertake any obligation to update publicly, or revise, forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Announcement. No statement in this Announcement is or is intended to be a profit forecast or profit estimate or to imply that the earnings of the Company for the current or future financial periods will necessarily match or exceed the historical or published earnings of the Company. The price of Ordinary Shares and the income from them may go down as well as up and investors may not get back the full amount invested on disposal of the Ordinary Shares.

It is not expected that any Convertible Loan Notes will be admitted to trading on any stock exchange. This Announcement is not an offering document, prospectus, prospectus equivalent document.

Neither the content of the Company's website nor any links on the Company's website is incorporated in, or forms part of, this Announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

ReleaseID: 617283

BOCA RATON, FL / ACCESSWIRE / November 18, 2020 / Xeriant, Inc. (OTC PINK:XERI), a new aerospace technology holding company, announced today that an additional utility patent has been issued by the U.S. Patent and Trademark Office related to its Halo aircraft technology, strengthening its October 2019 patent. Both utility patents are retroactive to Halo's original 2007 continuation patent application date, and therefore have the benefit of preceding numerous drone or UAV (unmanned aerial vehicle) patent filings and claims.

Halo is a development-stage eVTOL (electric vertical takeoff and landing) powered lift aircraft that has been designed to seamlessly transition from vertical to forward flight by altering the direction of its propulsive thrust by approximately 90 degrees. Powered lift aircraft combine the VTOL capability and small logistical footprint of helicopters with the cruise speed, fuel efficiency and range of conventional fixed wing airplanes. Halo's unique and scalable tiltwing configuration, which features a pivoting cylindrical wing structure and a central axle-mounted payload area, can also accommodate a range of propulsion systems, including ducted lift fans and distributed electric rotors, as well as various stability and control systems.

When fully developed, Xeriant plans to introduce the innovative Halo platform as a small high-performance UAV for commercial applications such as inspections, surveying, surveillance, delivery and imagery, which is expected to compete favorably with other eVTOL UAV aircraft in terms of speed, acoustics, payload, maneuverability, efficiency, range and safety. Depending on the success of the small UAV model, Xeriant may begin to develop a larger scale Halo aircraft model for the emerging UAM (urban air mobility) market or a variant for military applications. UAM, which is part of advanced air mobility, refers to on-demand passenger or cargo transport in congested environments.

Halo was chosen to be a finalist presenter, out of approximately 70 companies, at the November 2019 Florida Aerospace Capital Forum.

"UAVs represent one of the most dynamic growth sectors in aerospace, with applications expanding into almost every industry. Empowered by innovation, these new aerial vehicles promise to make aviation a greater part of our daily lives. The additional patent protection on the Halo technology supports our efforts to establish a strong position in this space," stated Xeriant CEO, Keith Duffy.

Read this and more news for Xeriant and Halo at: www.xeriant.com and www.xeriant.com/about/halo-aircraft

ABOUT XERIANT

Xeriant, Inc. (d.b.a. Xeriant Aerospace) is a holding and operating company focused on acquiring, developing, and commercializing revolutionary, eco-friendly technologies with applications in aerospace, including innovative aircraft concepts targeting emerging opportunities within the aviation industry. In 2019, Xeriant acquired a unique, scalable, multi-purpose VTOL aerial platform called Halo, which is protected under a broad utility patent. Xeriant is located at the Research Park at Florida Atlantic University in Boca Raton, Florida adjacent to the Boca Raton Airport. The Company is an OTC Markets public company trading under the stock symbol, XERI.

SAFE HARBOR FORWARD-LOOKING STATEMENTS

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Xeriant, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations concerning our ability to attract investors.

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

XERIANT, INC. CORPORATE

Keith Duffy, CEO
Innovation Centre #1
3998 FAU Blvd., Suite 309
Boca Raton, FL 33431
561-491-9595
corporate@xeriant.com
www.xeriant.com

SOURCE: Xeriant, Inc.

ReleaseID: 616611

HOUSTON, TX / ACCESSWIRE / November 18, 2020 / Memgen, a private biotechnology company developing novel treatments for cancer and COVID-19, today announced that John Poulos has joined the company's Board of Directors.

"I am very pleased to join the board of Memgen at this transformational time in the company's life," noted Mr. Poulos. "Memgen's strong and differentiated science hold promise both for patients with cancer and for an approach to COVID-19 that should be complementary to other approaches to vaccination. I look forward to helping the leadership team move these important treatments forward for the benefit of patients."

Dr. Gregory Brown, Memgen's CEO, also noted, "We are delighted to have John bring his extraordinary breadth of background and deep pharmaceutical expertise to bear as a member of Memgen's board. We are confident that John will add tremendous value as a director both in supporting the company's scientific progress and helping achieve positive business outcomes for the company."

Mr. Poulos has a wealth of expertise in global corporate life sciences, having spent 38 years working for AbbVie and Abbott. Mr. Poulos served as Vice President, Head of Business Development and Acquisitions for AbbVie from 2013 until his retirement in 2016. John was also Group Vice President, Head of Pharmaceutical Licensing and Acquisitions for Abbott from 2005 until 2012. During his career with AbbVie and Abbott, John was instrumental in the negotiation of numerous acquisitions, including Knoll/BASF Pharma in 2001 for $6.9 billion, Kos Pharmaceuticals in 2006 for $3.7 billion, Solvay in 2010 for $6.2 billion and Pharmacyclics in 2015 for $21 billion. He also has negotiated numerous partnerships and transactions which were instrumental in building the Abbott/AbbVie pharmaceutical portfolio.

Mr. Poulos is currently President of GNK Advisors, a business development consulting firm, and on the board of Faron Pharmaceuticals Oy. Mr. Poulos earned a bachelor's degree in marketing and an MBA in finance from Indiana University and was named the 2014 Frank Barnes Mentor Award recipient by the Licensing Executives Society.

About Memgen

Memgen is developing viral immunotherapies to harness the power of the immune system to cure cancer and to protect people from COVID-19 and other diseases. Its first-in-class immune-oncology therapeutics are designed for the treatment of patients who do not respond to currently available therapeutic options. The Company's lead cancer product, MEM-288, is engineered to both selectively target cancer cells and supercharge the immune system through expression of two unique and powerful immune modulators: CD40 ligand (CD40L) and the powerful cytokine interferon beta. MEM-288 has been demonstrated to generate a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. The Company expects to begin clinical testing with MEM-288 early in the coming year. Memgen's COVID-19 vaccine adjuvant, MemVax, is designed to be used with other vaccine technologies to generate a strong, durable immune response to protect against COVID-19 and other infectious diseases. The Company's pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already been tested in human subjects and has demonstrated the ability to elicit powerful, antigen-specific anti-tumor immune responses across a broad range of tumor types.

In this press release, unless the context requires otherwise, "Memgen," the "Company," "Companies," "we," "our," and "us" refers to Memgen, Inc.

Investor Contact:

Gregory B. Brown, M.D.
(203) 940-3742
gbrown@memgenbio.com

Media Contacts:

Gregory B. Brown, M.D.
(203) 940-3742
gbrown@memgenbio.com

SOURCE: Memgen

ReleaseID: 617140